Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.77 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 3/20 | 0.70 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.69 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236258 | 0.93 | TMEM97 (0.86) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2900269 | 0.93 | TMEM97 (0.86) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL61848 | 0.91 | TMEM97 (0.83) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL694949 | 0.91 | SIGMAR1 (0.82) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2233466 | 0.88 | KCNH2 (0.80) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7218186 | 0.88 | DRD4 (0.86) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8274001 | 0.87 | MEN1 (0.78) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2233461 | 0.87 | TMEM97 (0.77) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7224869 | 0.87 | SIGMAR1 (0.77) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1425074 | 0.87 | SIGMAR1 (1.00) | SIGMAR1TMEM97CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142703-B1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2023-10-18 | — | — | EP | claimed |
| US-20230270695-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-08-31 | — | — | US | claimed |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | UNM RAINFOREST INNOVATIONS (US) | 2023-08-24 | — | — | US | claimed |
| EP-4142703-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2023-03-08 | — | — | EP | claimed |
| WO-2021234324-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2021-11-25 | — | — | WO | claimed |
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| EP-3104847-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | Mta Támogatott Kutatócsoportok Irodája (HU) | 2016-12-21 | — | — | EP | claimed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | claimed |
| WO-2015118365-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2015-08-13 | — | — | WO | claimed |
| US-6517811-B2 | Diagnosing a mammal for presence of a tumor by administering compounds such as 125-I-(2-piperidinylaminoethyl)-4-iodobenzamide which have an affinity for cell surface sigma receptors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-02-11 | — | — | US | claimed |
| US-12611387-B2 | Compound and composition for inducing neuroprotection | REST THERAPEUTICS (FR) | 2026-04-28 | — | — | US | disclosed |
| EP-4176869-B1 | PREPARATION AND USE OF CANNABIS NANO-FORMULATION | APURANO PHARMACEUTICALS GMBH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4523686-A1 | A SIGMA-1 RECEPTOR POSITIVE MODULATOR FOR ITS USE IN THE PREVENTION AND THE TREATMENT OF A PATHOLOGY | UNIVERSITE DE MONTPELLIER (FR) | 2025-03-19 | — | — | EP | disclosed |
| US-12239125-B2 | Compositions for organ preservation | SigmaDrugs Kutató Korlátolt Felelsség Társaság (HU) | 2025-03-04 | — | — | US | disclosed |
| US-12208127-B2 | Preparation and use of cannabis nano-formulation | APURANO PHARMACEUTICALS GMBH (DE) | 2025-01-28 | — | — | US | disclosed |
| US-5993777-A | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5919934-A | BISAMINOTHIOL AND AMINO COMPOUNDS WITH APPENDED PHARMACOPHORES, METAL COMPLEXES OF THESE COMPOUNDS; | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270695-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | BDNF, GAP43, NLN | SIGMAR1 1214/4885TMEM97 1922/4885CYP1A2 4080/4885 |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | SARS1, SQSTM1, ATG4A | SIGMAR1 2480/4885TMEM97 655/4885CYP1A2 4798/4885 |
| US-12611387-B2 | Compound and composition for inducing neuroprotection | GAP43, BDNF, NEFM | SIGMAR1 58/4885TMEM97 67/4885CYP1A2 2314/4885 |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885TMEM97 2/4885CYP1A2 896/4885 |
| US-12239125-B2 | Compositions for organ preservation | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885TMEM97 2/4885CYP1A2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.